18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: A retrospective analysis

European Radiology

Volumn 20, Issue 4, 2010, Pages 923-930

  Bannas, Peter ^a   Weber, Christoph ^a   Derlin, Thorsten ^a   Lambert, Jörg ^a   Leypoldt, Frank ^a   Adam, Gerhard ^a   Mester, Janos ^a   Klutmann, Susanne ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

18F FDG PET; 18F FDG PET CT; Computed tomography; Paraneoplastic neurological syndrome (PNS); Positron emission tomography

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GASTROLUX CT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS POTENTIAL; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VASCULAR DISEASE; IMAGE SUBTRACTION; METHODOLOGY; MIDDLE AGED; NEUROLOGIC DISEASE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77952090969     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1606-0     Document Type: Article

References (32)

1. RB Darnell JB Posner 2003 Paraneoplastic syndromes involving the nervous system N Engl J Med 349 1543 1554 10.1056/NEJMra023009 1:CAS:528: DC%2BD3sXotFGhs78%3D 14561798 (Pubitemid 37255041)
2. R Voltz 2002 Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy Lancet Neurol 1 294 305 10.1016/S1474-4422(02)00135-7 12849427 (Pubitemid 37159173)
3. F Graus JY Delattre JC Antoine J Dalmau B Giometto W Grisold J Honnorat PS Smitt C Vedeler JJ Verschuuren A Vincent R Voltz 2004 Recommended diagnostic criteria for paraneoplastic neurological syndromes J Neurol Neurosurg Psychiatry 75 1135 1140 10.1136/jnnp.2003.034447 1:STN:280:DC%2BD2czlsFGitg%3D%3D 15258215 (Pubitemid 39005770)
4. R Voltz F Graus 2004 Diagnosis and treatment of paraneoplastic neurological disorders Onkologie 27 253 258 10.1159/000077975 1:STN:280:DC%2BD2czks1Ohsw%3D%3D 15249714 (Pubitemid 39279334)
5. F Graus F Keime-Guibert R Rene B Benyahia T Ribalta C Ascaso G Escaramis JY Delattre 2001 Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients Brain 124 1138 1148 10.1093/brain/124.6.1138 1:STN:280:DC%2BD3MzktFOlug%3D%3D 11353730 (Pubitemid 32510382)
6. F Keime-Guibert F Graus A Fleury R Rene J Honnorat P Broet JY Delattre 2000 Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone J Neurol Neurosurg Psychiatry 68 479 482 10.1136/jnnp.68.4.479 1:STN:280:DC%2BD3c7ptlOhsw%3D%3D 10727484 (Pubitemid 30248748)
7. WP Mason F Graus B Lang J Honnorat JY Delattre F Valldeoriola JC Antoine MK Rosenblum MR Rosenfeld J Newsom-Davis JB Posner J Dalmau 1997 Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome Brain 120 1279 1300 10.1093/brain/120.8.1279 9278623 (Pubitemid 27344700)
8. J Dalmau F Graus MK Rosenblum JB Posner 1992 Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients Medicine (Baltimore) 71 59 72 1:STN:280:DyaK387os1Kquw%3D%3D
9. CF Lucchinetti DW Kimmel VA Lennon 1998 Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies Neurology 50 652 657 1:STN:280:DyaK1c7otVGntQ%3D%3D 9521251 (Pubitemid 28146144)
10. C Chartrand-Lefebvre N Howarth P Grenier F Keime B Orcel C Beigelman 1998 Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings AJR Am J Roentgenol 170 1513 1517 1:STN:280:DyaK1c3ntVehtQ%3D%3D 9609164 (Pubitemid 28237640)
11. S Basu A Alavi 2008 Unparalleled contribution of 18F-FDG PET to medicine over 3 decades J Nucl Med 49 17N 21N 10.2967/jnumed.108.050401 18832112 37N (Pubitemid 351793447)
12. JB Bomanji DC Costa PJ Ell 2001 Clinical role of positron emission tomography in oncology Lancet Oncol 2 157 164 10.1016/S1470-2045(00)00257-6 1:STN:280:DC%2BD387ntFeltg%3D%3D 11902566 (Pubitemid 33585927)
13. BE Hillner BA Siegel D Liu AF Shields IF Gareen L Hanna SH Stine RE Coleman 2008 Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry J Clin Oncol 26 2155 2161 10.1200/JCO.2007.14.5631 18362365
14. JH Rees SF Hain MR Johnson RA Hughes DC Costa PJ Ell G Keir P Rudge 2001 The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders Brain 124 2223 2231 10.1093/brain/124.11. 2223 1:STN:280:DC%2BD3Mrms12isw%3D%3D 11673324 (Pubitemid 33055367)
15. S Younes-Mhenni MF Janier L Cinotti JC Antoine F Tronc V Cottin PJ Ternamian P Trouillas J Honnorat 2004 FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes Brain 127 2331 2338 10.1093/brain/awh247 1:STN:280:DC%2BD2cvnsVCntA%3D%3D 15361417 (Pubitemid 39382241)
16. JC Antoine L Cinotti C Tilikete F Bouhour JP Camdessanche C Confavreux A Vighetto V Renault-Mannel D Michel J Honnorat 2000 [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies Ann Neurol 48 105 108 10.1002/1531-8249(200007)48:1<105::AID-ANA16>3.0.CO;2-G 1:STN:280:DC%2BD3czltVOhsw%3D%3D 10894223 (Pubitemid 30432438)
17. RR Patel RM Subramaniam JN Mandrekar JE Hammack VJ Lowe JR Jett 2008 Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis Mayo Clin Proc 83 917 922 10.4065/83.8.917 18674476
18. U Berner C Menzel D Rinne S Kriener N Hamscho N Dobert M Diehl R Kaufmann F Grunwald 2003 Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET Q J Nucl Med 47 85 89 1:STN:280:DC%2BD3szjtlKiuw%3D%3D 12865868 (Pubitemid 36998714)
19. G Antoch J Stattaus AT Nemat S Marnitz T Beyer H Kuehl A Bockisch JF Debatin LS Freudenberg 2003 Non-small cell lung cancer: dual-modality PET/CT in preoperative staging Radiology 229 526 533 10.1148/radiol.2292021598 14512512 (Pubitemid 37310842)
20. R Bar-Shalom N Yefremov L Guralnik D Gaitini A Frenkel A Kuten H Altman Z Keidar O Israel 2003 Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management J Nucl Med 44 1200 1209 12902408 (Pubitemid 39655178)
21. DW Townsend 2008 Dual-modality imaging: combining anatomy and function J Nucl Med 49 938 955 10.2967/jnumed.108.051276 18483101 (Pubitemid 351793435)
22. GK Von Schulthess TF Hany 2008 Imaging and PET-PET/CT imaging J Radiol 89 438 447 quiz 448
23. M Frings G Antoch P Knorn L Freudenberg U Bier D Timmann M Maschke 2005 Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration J Neurol 252 197 201 10.1007/s00415-005- 0635-0 15729526 (Pubitemid 40385594)
24. KA Miles 2008 PET-CT in oncology: making the most of CT Cancer Imaging 8 Suppl AS87 93
25. M Hadjivassiliou SJ Alder EJ Van Beek MB Hanney E Lorenz DG Rao B Sharrack WB Tindale 2009 PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit Acta Neurol Scand 119 186 193 10.1111/j.1600-0404.2008.01089.x 1:STN:280:DC%2BD1M7ht1Kkuw%3D%3D 18855873
26. R Linke M Schroeder T Helmberger R Voltz 2004 Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis Neurology 63 282 286 15277621 (Pubitemid 38971127)
27. RB Darnell LM DeAngelis 1993 Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies Lancet 341 21 22 10.1016/0140-6736(93)92485-C 1:STN:280:DyaK3s7gvV2ksQ%3D%3D 8093269 (Pubitemid 23007597)
28. GJ Cook EA Wegner I Fogelman 2004 Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging Semin Nucl Med 34 122 133 10.1053/j.semnuclmed.2003. 12.003 15031812 (Pubitemid 38375467)
29. MM Abouzied ES Crawford HA Nabi 2005 18F-FDG imaging: pitfalls and artifacts J Nucl Med Technol 33 145 155 16145222 quiz 162-143
30. G Antoch LS Freudenberg T Beyer A Bockisch JF Debatin 2004 To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT J Nucl Med 45 Suppl 156S 165S
31. V Rufini ML Calcagni RP Baum 2006 Imaging of neuroendocrine tumors Semin Nucl Med 36 228 247 10.1053/j.semnuclmed.2006.03.007 16762613 (Pubitemid 43817847)
32. SJ Goldsmith 2009 Update on nuclear medicine imaging of neuroendocrine tumors Future Oncol 5 75 84 10.2217/14796694.5.1.75 1:CAS:528: DC%2BD1MXitlyltbc%3D 19243300